Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation
Mahmoud M. Iravani, Peter Jenner
Journal of Neural Transmission (2011) Vol. 118, Iss. 12, pp. 1661-1690
Closed Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

The Lipophilic Bullet Hits the Targets: Medicinal Chemistry of Adamantane Derivatives
Lukas Wanka, Khalid Iqbal, Peter R. Schreiner
Chemical Reviews (2013) Vol. 113, Iss. 5, pp. 3516-3604
Open Access | Times Cited: 597
Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
Destany K. Kwon, Mohit Kwatra, Jing Wang, et al.
Cells (2022) Vol. 11, Iss. 23, pp. 3736-3736
Open Access | Times Cited: 78
Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease
Susan H. Fox
Drugs (2013) Vol. 73, Iss. 13, pp. 1405-1415
Closed Access | Times Cited: 140
Glial activation is associated with l-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson's disease
Mariza Bortolanza, Roberta Cavalcanti-Kiwiatkoski, Fernando E. Padovan‐Neto, et al.
Neurobiology of Disease (2014) Vol. 73, pp. 377-387
Closed Access | Times Cited: 107
Cannabinoid–dopamine interactions in the physiology and physiopathology of the basal ganglia
Concepción García, Cristina Palomo‐Garo, Yolanda Gómez‐Gálvez, et al.
British Journal of Pharmacology (2015) Vol. 173, Iss. 13, pp. 2069-2079
Open Access | Times Cited: 94
Management of Parkinson׳s disease: Current and future pharmacotherapy
Ashish Kumar Kakkar, Neha Dahiya
European Journal of Pharmacology (2015) Vol. 750, pp. 74-81
Closed Access | Times Cited: 84
l-DOPA-treatment in primates disrupts the expression of A2A adenosine–CB1 cannabinoid–D2 dopamine receptor heteromers in the caudate nucleus
Jordi Bonaventura, Alberto J. Rico, Estefanía Moreno, et al.
Neuropharmacology (2013) Vol. 79, pp. 90-100
Closed Access | Times Cited: 83
Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
Angelo Antonini, Victor S.C. Fung, James T. Boyd, et al.
Movement Disorders (2016) Vol. 31, Iss. 4, pp. 530-537
Open Access | Times Cited: 81
Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans
Damian M. Herz, Brian N. Haagensen, Mark Schram Christensen, et al.
Brain (2015) Vol. 138, Iss. 6, pp. 1658-1666
Open Access | Times Cited: 76
Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3−/− aphakia mice
Óscar Solís, Isabel Espadas, Elaine Aparecida Del Bel, et al.
Neurobiology of Disease (2014) Vol. 73, pp. 49-59
Closed Access | Times Cited: 71
Gait Progression Over 6 Years in Parkinson’s Disease: Effects of Age, Medication, and Pathology
Joanna Wilson, Lisa Alcock, Alison J. Yarnall, et al.
Frontiers in Aging Neuroscience (2020) Vol. 12
Open Access | Times Cited: 66
Striatal plasticity in Parkinson's disease and L-DOPA induced dyskinesia
Mahmoud M. Iravani, Andrew C. McCreary, Peter Jenner
Parkinsonism & Related Disorders (2011) Vol. 18, pp. S123-S125
Closed Access | Times Cited: 70
Modeling Parkinson's disease in monkeys for translational studies, a critical analysis
Lisa F. Potts, Hao Wu, Arun Singh, et al.
Experimental Neurology (2013) Vol. 256, pp. 133-143
Open Access | Times Cited: 70
Metabotropic Glutamate Receptors for Parkinson's Disease Therapy
F. Gasparini, Thérèse Di Paolo, Baltazar Gomez‐Mancilla
Parkinson s Disease (2013) Vol. 2013, pp. 1-11
Open Access | Times Cited: 62
Alpha-lipoic acid protects against 6-hydroxydopamine-induced neurotoxicity in a rat model of hemi-parkinsonism
Mohammadreza Jalali Nadoushan, Mehrdad Roghani
Brain Research (2013) Vol. 1505, pp. 68-74
Closed Access | Times Cited: 59
Nicotine reduces established levodopa‐induced dyskinesias in a monkey model of Parkinson's disease
Maryka Quik, Archana Mallela, Jason Ly, et al.
Movement Disorders (2013) Vol. 28, Iss. 10, pp. 1398-1406
Open Access | Times Cited: 57
Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats
Weien Yuan, Xinxin Yang, Ruiyuan Zheng, et al.
International Journal of Nanomedicine (2012), pp. 2077-2077
Open Access | Times Cited: 52
Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
Eva Schaeffer, Andrea Pilotto, Daniela Berg
CNS Drugs (2014) Vol. 28, Iss. 12, pp. 1155-1184
Closed Access | Times Cited: 51
Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, l-DOPA Responsivity, and Glutamatergic Neurotransmission
Alexandra Alvarsson, Xiaoqun Zhang, Tiberiu Loredan Stan, et al.
Journal of Neuroscience (2015) Vol. 35, Iss. 41, pp. 14057-14069
Open Access | Times Cited: 49
Multiple CNS nicotinic receptors mediate l-dopa-induced dyskinesias: Studies with parkinsonian nicotinic receptor knockout mice
Maryka Quik, Carla Cristian Campos, Sharon R. Grady
Biochemical Pharmacology (2013) Vol. 86, Iss. 8, pp. 1153-1162
Open Access | Times Cited: 47
Nicotinic Receptor Agonists Reduce l-DOPA–Induced Dyskinesias in a Monkey Model of Parkinson's Disease
Danhui Zhang, Archana Mallela, David Sohn, et al.
Journal of Pharmacology and Experimental Therapeutics (2013) Vol. 347, Iss. 1, pp. 225-234
Open Access | Times Cited: 47
ABT‐089 and ABT‐894 reduce levodopa‐induced dyskinesias in a monkey model of Parkinson's disease
Danhui Zhang, Tanuja Bordia, Matthew McGregor, et al.
Movement Disorders (2014) Vol. 29, Iss. 4, pp. 508-517
Open Access | Times Cited: 43
α4β2 nicotinic receptors play a role in the nAChR-mediated decline in l-dopa-induced dyskinesias in parkinsonian rats
Maryka Quik, Carla Cristian Campos, Tanuja Bordia, et al.
Neuropharmacology (2013) Vol. 71, pp. 191-203
Open Access | Times Cited: 44
Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function
Maryka Quik, Archana Mallela, M C Chin, et al.
Neurobiology of Disease (2012) Vol. 50, pp. 30-41
Open Access | Times Cited: 43
Wearing Off, Dyskinesia, and the Use of Continuous Drug Delivery in Parkinson's Disease
Peter Jenner
Neurologic Clinics (2013) Vol. 31, Iss. 3, pp. S17-S35
Open Access | Times Cited: 41
Page 1 - Next Page

Scroll to top